Ehave Couples KetaDASH with Digital Therapeutics Expertise to Combat Clinical Depression
February 01, 2021 08:30 ET
|
Ehave
MIAMI, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, is announcing plans to roll...
Ehave Looks to Expand KetaDASH to Palliative Care
January 27, 2021 08:30 ET
|
Ehave
MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it is...
Ehave Closes Transaction to Acquire CureDash Assets, Adds KetaDASH Home Delivery Service for Ketamine Clinics
January 22, 2021 08:30 ET
|
Ehave
MIAMI, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it completed...
Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector
January 20, 2021 08:30 ET
|
Ehave
MIAMI, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics, announced today the Company has closed the transaction to sell 100% of its...
Franciosi Consulting Reviewing the Science and History of Psychedelic Drug Use for Treating Depression, Anxiety and Addiction
January 04, 2021 20:28 ET
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Lui Franciosi of Franciosi Consulting Ltd. has been intrigued with the growing interest in the use of psychedelic drugs for treating...
Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value
December 28, 2020 08:30 ET
|
Ehave
MIAMI, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics and developer of KetaDASH, a home delivery platform for patients who have...
Ehave KetaDASH Subsidiary Announces Intent to Battle Major Depression through Home Delivery of Ketamine
December 23, 2020 08:30 ET
|
Ehave
Ketamine, originally approved by the FDA for anesthesia and pain relief, is now one of the psychedelics compounds being studied to treat mental health conditions like anxiety, addiction, and...
The Next Leg in the Bull Market for Psychedelic Stocks
December 21, 2020 08:00 ET
|
OTC Stock Review
ATLANTA, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Santa Claus came early this year as shares in psychedelic companies like Mind Medicine (MindMed) Inc. (OTCQB: MMEDF), Ehave, Inc. (OTC Pink: EHVVF),...
Ehave, Inc. Issues CEO Letter to Stockholders, Reports on Significant Progress and Outlook for 2021
December 17, 2020 08:30 ET
|
Ehave
MIAMI, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients, announces...
Ehave, Inc. Announces KetaDASH for Ketamine Home Delivery and Purchase of Curedash Assets
December 16, 2020 08:30 ET
|
Ehave
MIAMI, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients, today...